The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC).
 
Andrea Necchi
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Pierre Fabre; Seagen
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Celgene; Merck Sharp & Dohme; Roche
 
Daniele Raggi
No Relationships to Disclose
 
Salvatore Lo Vullo
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Elena Togliardi
No Relationships to Disclose
 
Nicola Nicolai
No Relationships to Disclose
 
Federica Perrone
No Relationships to Disclose
 
Giuseppe Pelosi
No Relationships to Disclose
 
Roberto Salvioni
No Relationships to Disclose
 
Filippo G. De Braud
No Relationships to Disclose